PedAM
Pediatric Disease Annotations & Medicines
| Disease | liver disease |
| Symptom | C0011849|diabetes mellitus |
| Sentences | 24 |
| PubMedID- 26381272 | Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. |
| PubMedID- 25877002 | The aggravation of mitochondrial dysfunction in nonalcoholic fatty liver disease accompanied with type 2 diabetes mellitus. |
| PubMedID- 26573192 | Body mass index is a risk factor for new-onset non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. |
| PubMedID- 22927782 | The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. |
| PubMedID- 25120322 | Relationship of liver stiffness and controlled attenuation parameter measured by transient elastography with diabetes mellitus in patients with chronic liver disease. |
| PubMedID- 20625647 | Objective: to evaluate the frequency of non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (dm2) and to describe its risk factors. |
| PubMedID- 25885947 | High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. |
| PubMedID- 24071688 | Objective: to observe the effect of metformin on the expression of sirt1 and ucp2 in rat liver of type 2 diabetes mellitus (t2dm) with nonalcoholic fatty liver disease (nafld), and discuss the pathogenesis of t2dm with nafld, and the treatment with and possible mechanism of metformin. |
| PubMedID- 23954219 | Objective: to investigate the relationship between the resistin intronic +299g/a polymorphism and nonalcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 26339423 | Prognostic value of high sensitivity c-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease. |
| PubMedID- 26573193 | Objective: to explore the relationship between socioeconomic status (ses) and non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 26198953 | Objective: to investigate the association of serum pigment epithelium-derived factor (pedf) level and polymorphisms in pedf gene promoter region -358g-->a with non-alcoholic fatty liver disease (nafld) in patients with type 2 diabetes mellitus (t2dm) of han nationality in fujian province. |
| PubMedID- 24667697 | The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. |
| PubMedID- 26147768 | Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. |
| PubMedID- 22024083 | Sitagliptin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. |
| PubMedID- 26005676 | Fatty liver disease in diabetes mellitus. |
| PubMedID- 21642744 | Akr1b7 may be a therapeutic target for treatment of fatty liver disease associated with diabetes mellitus. |
| PubMedID- 22025861 | Effect of silymarin in diabetes mellitus patients with liver diseases. |
| PubMedID- 23489256 | Aim: the aim of this case-control study was to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (t2dm) with non-alcoholic fatty liver disease (nafld). |
| PubMedID- 20736249 | In this study, we examined serum 1,5-ag levels in chronic liver disease (cld) patients with and without diabetes mellitus. |
| PubMedID- 25303488 | High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. |
| PubMedID- 24919218 | Advancement of researches on association of non-alcoholic fatty liver disease with type 2 diabetes mellitus. |
| PubMedID- 21435130 | The aim of this case-control study is to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (t2dm) with chronic liver disease caused by hcv. |
| PubMedID- 24912965 | The morbidity and associated risk factors of cancer in chronic liver disease patients with diabetes mellitus: a multicenter field survey. |
Page: 1